Biotech & Life Sciences
-
Investors Eye Proteins Market: 9.5% Annual Growth Through 2030
Executive Summary The proteins and protein crystals market has become one of the most important pillars of modern biotechnology and biopharmaceuticals. Growth is being driven by rising demand for therapeutic proteins, advances in structural biology, and expanding use across healthcare, agriculture, food processing, and industrial applications. According to MarketsandMarkets, the market is expected to grow
-
Sephora Welcomes AESTURA’s Fastest-Growing Redness-Reducing Skincare Line
AESTURA, Korea’s top dermatologist-recommended dermocosmetic brand for sensitive skin, has announced the launch of A-CICA365, a three-product collection designed to soothe skin and visibly reduce redness. The new collection expands AESTURA’s partnership with Sephora and will be available in all Sephora stores nationwide throughout 2026. Growing U.S. Demand Since entering Sephora in February 2025, AESTURA
-
Facial Injectables Dominate 55% of the Market: Botox, Fillers, and Skin Rejuvenation on the Rise
Executive Summary The global medical aesthetics market is growing quickly. Rising demand for minimally invasive and non-surgical treatments, combined with new technology in injectables and energy-based devices, is driving expansion. Consumers are more comfortable than ever with aesthetic procedures, influenced by social media, lifestyle trends, and an aging population. MarketsandMarkets projects the market to grow
-
FDA Clears First Nerve-Specific Fluorescent Agent for Human Trials
Trace Biosciences, Inc., a clinical-stage biotechnology company focused on nerve-targeted imaging, announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (IND) application for LGW16-03, the company’s first nerve-specific fluorescent imaging agent. This clearance allows Trace to begin first-in-human studies to assess the safety and performance of LGW16-03 during surgery. Helping
-
Paytient’s Innovative Payment Solutions Earn Top Recognition in 2025
Paytient, a leader in healthcare affordability and payment solutions, was recognized with Modern Healthcare’s 2025 Best in Business Award in the Patient Experience and Engagement category. The award underscores Paytient’s role as a critical infrastructure partner for insurers and employers, helping bridge the gap between health coverage and access, particularly through the company’s Medicare Prescription
-
Expert Radiation Shielding for Hospitals and Imaging Centers Across the U.S.
Lead Glass Pro, a U.S.-based supplier of radiation shielding products, is continuing to expand its capabilities to support hospitals, imaging centers, and construction teams across the country. The company provides materials and technical expertise for X-ray, CT, fluoroscopy, cath lab, nuclear medicine, and interventional imaging rooms. Medical imaging construction projects require strict compliance with federal,
-
Breakthrough in Wound Care: MolecuLightDX Earns FDA MDDT Status
MolecuLight announced that its MolecuLightDX® wound measurement system has been qualified by the U.S. Food and Drug Administration (FDA) as a Medical Device Development Tool (MDDT). This program validates scientifically proven tools for use in medical device development, allowing sponsors to generate reliable, FDA-accepted data during clinical trials. What This Means MolecuLightDX: A Unique Wound
-
Intellia Stock Rises on FDA Clearance for CRISPR Therapy
NTLA performance by TradingView Intellia Therapeutics (NASDAQ: NTLA) saw shares rise after the FDA lifted a clinical hold on one of its Phase 3 trials for nexiguran ziclumeran (nex-z), a CRISPR-based therapy for transthyretin amyloidosis (ATTR). What Happened Last October, U.S. regulators paused two trials after a participant died from severe liver toxicity. The cleared
-
From Biotech CEO to Prison: Inside the CytoDyn Fraud Case
CYDY performance by TradingView A former biotech executive has been sentenced to prison after being found guilty of misleading investors and selling his own shares at inflated prices. Nader Pourhassan, 62, of Lake Oswego, Oregon, was sentenced to 30 months in federal prison for securities fraud related to false claims about a drug his company
-
New LEQEMBI Shot Lets Alzheimer’s Patients Skip Clinic Visits
BIIB performance by TradingView Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) announced that the FDA has accepted a review for their new subcutaneous (under-the-skin) version of LEQEMBI, called LEQEMBI IQLIK, for people with early Alzheimer’s disease. The FDA has given it Priority Review, with a decision expected by May 24, 2026. If approved, this version
